A contingent value right, or CVR, is a contractual right given to shareholders of a company being acquired that entitles them to an additional payment later if a specific milestone is met by a set deadline. If the milestone is hit, the acquirer pays a defined amount per CVR. If it is not, the CVR expires and pays nothing. CVRs exist because buyer and seller often disagree about what an unproven asset — a drug in development, a pending lawsuit, a product not yet at scale — is really worth, and a CVR splits that disagreement into a guaranteed part paid now and a conditional part paid only if the asset delivers.
How the Payment Mechanic Works
In a merger that uses a CVR, the purchase price arrives in two pieces. The upfront piece — cash, acquirer stock, or a mix — transfers at closing the way any acquisition consideration would. The conditional piece is the CVR: each share of the target company typically converts into one CVR at closing, and each CVR pays a specified amount if defined events occur within a defined window.
The structure is all-or-nothing at each milestone. There is no partial payment for near misses, and there is no appeal from the deadline. Because of that, the exact wording of the milestone in the merger documents controls everything that follows. Small drafting differences have produced major litigation, and courts read milestone language literally rather than by its spirit.
Tradable and Nontradable CVRs
CVRs come in two forms, and which one you hold changes what you can do with it.
A tradable CVR is listed on a public exchange such as the NYSE or Nasdaq. You can sell it before the milestone deadline and take whatever the market will pay, which is almost always well below the maximum potential payout because the price reflects the probability that the milestone will actually be achieved, discounted for time and uncertainty. Because tradable CVRs trade publicly, the issuer must register them with the SEC.
A nontradable CVR cannot be transferred or sold. It stays with the shareholders who owned the target at closing and functions as a private contract with the acquirer. Most recent CVR deals have used nontradable structures because they avoid registration costs and ongoing SEC reporting. If you hold a nontradable CVR, your only route to any value is waiting for the milestone.
What Triggers a Payment
Payouts depend on objective milestones written into the merger agreement. The common categories are:
- Regulatory approval, most often FDA approval of a specific drug for a specified condition by a set deadline.
- Revenue targets, such as exceeding a defined level of annual net sales of a particular product within a measuring period.
- Litigation outcomes, such as a judgment or settlement above a threshold in a pending case.
- Clinical or technical milestones, such as completing a clinical trial or hitting production volume targets by a given date.
Some agreements pay a flat dollar amount per CVR when a milestone is achieved. Others use tiered formulas — for example, 2.5% of net sales between $1 billion and $2 billion plus 5% of net sales above $2 billion.1Bristol Myers Squibb. Acquisition FAQs for Celgene Shareholders
Two Deals That Show the Range of Outcomes
Sanofi and Genzyme, 2011
Sanofi and Genzyme disagreed sharply on the value of Genzyme’s drug pipeline. The deal paid Genzyme shareholders $74 per share in cash at closing plus one tradable CVR per share worth up to $14 in additional payments tied to several milestones: FDA approval of Lemtrada for multiple sclerosis by March 31, 2014 ($1 per CVR), cumulative Lemtrada sales targets ranging from $400 million to $2.8 billion (up to $12 per CVR), and production targets for two other drugs by the end of 2011 ($1 per CVR).
Bristol Myers Squibb and Celgene, 2019
BMS’s acquisition of Celgene included a tradable CVR (NYSE ticker “BMY RT”) that would pay $9 in cash per CVR if the FDA approved three specific drugs: ozanimod by December 31, 2020, liso-cel by December 31, 2020, and ide-cel by March 31, 2021. All three approvals were required. The FDA did not approve liso-cel by its deadline, so the CVR agreement terminated automatically on January 1, 2021, and the CVRs expired worthless.1Bristol Myers Squibb. Acquisition FAQs for Celgene Shareholders Holders received nothing beyond the upfront deal consideration. The liso-cel approval came just weeks later, but the contract deadline had already passed.
Where to Find the Agreement and What to Read For
Every CVR is governed by a Contingent Value Rights Agreement filed with the SEC as an exhibit to the merger documents.2Securities and Exchange Commission. Contingent Value Rights Agreement You can find it by searching the SEC’s EDGAR database for the acquirer’s merger-related filings, usually attached to a Form 8-K or the merger registration statement. The provisions that actually govern whether you get paid are:
- The milestone definitions, including exact deadlines and how achievement is measured.
- The payment formula — flat per-CVR amount, revenue tier, or otherwise.
- The drop-dead date, after which all claims expire.
- The efforts standard. Many agreements require the acquirer to use “commercially reasonable efforts” to pursue the milestone, and the agreement itself defines that phrase, often by reference to what a similar company would do with a similar product at a similar stage, weighing market potential, development cost, competition, regulatory path, and expected profitability.3Securities and Exchange Commission. Contingent Value Rights Agreement
- The Rights Agent, a neutral third-party trustee (often a major trust company) that administers the agreement, verifies milestone achievement, and oversees payment.
Some agreements also let holders request an audit of the acquirer’s records to verify milestone-relevant data. A typical structure allows holders of at least 20% of outstanding CVRs to request one audit per year, paid for by the acquirer, with the auditor disclosing only whether a milestone was triggered.4Securities and Exchange Commission. Form of Contingent Value Rights Agreement
How Payment Reaches You
When a milestone is achieved, the acquirer notifies the Rights Agent, who independently verifies by reviewing financial statements, government approvals, or other relevant documentation. A payment notice then goes to registered holders through press releases and corporate filings.
If you hold a tradable CVR, payment flows automatically through the Depository Trust Company to your brokerage account, the same way exchange-listed dividends and distributions do.5DTCC. Distributions for Securities – Corporate Actions Processing If you hold a nontradable CVR, the Rights Agent sends payment directly by check or electronic transfer to the address on file. Payment may be cash, acquirer stock, or a combination, and the form is fixed at the time of the merger. Cash is most common.
Federal Tax Treatment
Receiving CVR proceeds is a taxable event. Which rules apply depends on whether the IRS treats the transaction as “closed” or “open,” and that turns on whether the CVR’s fair market value can be reasonably determined at the time of the merger.
Closed Transaction Treatment
If the CVR has a reasonably ascertainable fair market value — usually true for tradable CVRs that have a market price — you include that value as part of your total sale proceeds in the year of the merger and calculate gain or loss then. Your tax basis in the CVR equals that fair market value. When you later collect a milestone payment or sell the CVR, you recognize additional gain or loss against that basis. Any gain is long-term capital gain if you held the original shares for more than one year before the merger.6SEC.gov. Offer to Purchase – Section: Material U.S. Federal Income Tax Consequences
Open Transaction Treatment
If the CVR’s value cannot be reasonably determined, more common with nontradable CVRs, the transaction may qualify for open treatment. You recover your stock basis first as payments come in and only recognize gain once cumulative payments exceed your original basis. Treasury regulations treat open transaction status as appropriate only in rare and extraordinary cases.7SEC.gov. Offer to Purchase for All Outstanding Shares of Common Stock of Verve Therapeutics Inc
Imputed Interest
Because CVR payments are deferred, part of any payment you receive may be recharacterized as imputed interest rather than sale proceeds. When a contingent payment is made more than a certain period after the sale, the IRS treats a portion as interest income, taxed at ordinary income rates rather than capital gains rates.8eCFR. 26 CFR 1.483-4 – Contingent Payments The interest amount equals the difference between the payment’s value on the date received and its present value discounted back to the merger date using the applicable federal rate. Merger proxy statements typically walk through these consequences in detail, and it is worth consulting a tax advisor before the deal closes.
Risks You Take as a Holder
A CVR can look like free upside, but several risks bite in practice.
The milestone simply isn’t met. BMS-Celgene is the clean example: three approvals required, one missed by weeks, everything expired worthless.
The acquirer’s incentives change after closing. Once the deal is done, the acquirer captures little of the benefit from hitting a milestone that pays out to former target shareholders. It may deprioritize the product, reduce development funding, or make decisions that are rational for the combined company and bad for CVR holders. A “commercially reasonable efforts” clause is flexible, does not guarantee achievement, and may even permit terminating development if business conditions change.3Securities and Exchange Commission. Contingent Value Rights Agreement
Enforcement is hard. Many agreements require any legal action to be brought by a designated Holders’ Representative rather than individual holders.9Securities and Exchange Commission. Contingent Value Rights Agreement Courts have also been reluctant to order the acquirer to take specific development steps, because supervising those decisions calls for specialized scientific and commercial judgment.
Courts read milestones literally. In one case involving SARcode Bioscience, holders argued that the drug’s FDA approval should trigger payment. The court ruled against them because one specific clinical study had missed a required endpoint, even though other studies showed the same result and the drug was ultimately approved. The precise wording controlled.
Acquirer bankruptcy. If the acquiring company enters bankruptcy, CVR obligations are typically subordinated to other debts, and holders may receive nothing even if the milestone was met.
What Happens at Expiration or If You Don’t Claim
If the drop-dead date passes without the milestone being achieved, the agreement terminates and all rights under it are extinguished. The acquirer owes nothing more, and tradable CVRs stop trading. There is no appeals process and no extension unless the original agreement provides one.
When a milestone is achieved but individual holders fail to claim their payment, the unclaimed funds eventually fall under state unclaimed property laws. Most states require companies to turn over unclaimed financial assets, including uncollected securities distributions, after a dormancy period of three to five years depending on the jurisdiction. You can later reclaim the funds through your state’s unclaimed property office, but the process adds delay. Keeping your contact information current with your brokerage or the Rights Agent avoids the problem entirely.